These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 1902552)

  • 1. Recombinant factor VIII in hemophilia.
    Cohen A; Butler R
    N Engl J Med; 1991 May; 324(21):1515-6. PubMed ID: 1902552
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor VIII inhibitor and severity of hemophilia.
    Schoppmann A; Waytes AT
    Thromb Haemost; 1996 Aug; 76(2):280-1. PubMed ID: 8865549
    [No Abstract]   [Full Text] [Related]  

  • 3. World registry on factor VIII inhibitor patients: why?
    Aledort LM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):7-9. PubMed ID: 8480198
    [No Abstract]   [Full Text] [Related]  

  • 4. The current status of recombinant human factor VIII.
    Aronson DL
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131
    [No Abstract]   [Full Text] [Related]  

  • 5. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 7. [Recombinant factor VIII].
    Tusell JM
    Sangre (Barc); 1993 Apr; 38(2):139-42. PubMed ID: 8516727
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.
    Bray G
    Ann Hematol; 1994; 68 Suppl 3():S29-34. PubMed ID: 8180254
    [No Abstract]   [Full Text] [Related]  

  • 9. [Side-effects of factor VIII substitution in patients with hemophilia A (author's transl)].
    Tilsner V; Reuter H
    MMW Munch Med Wochenschr; 1982 Jun; 124(22):553-7. PubMed ID: 6808385
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy.
    Scharrer I; Neutzling O; Schwaab R; Oldenburg J; Ehrlich H
    Ann Hematol; 1998; 76 Suppl 1():A1-6. PubMed ID: 9542469
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant porcine factor VIII: a new installment of a long story.
    Mannucci PM
    Haemophilia; 2015 Mar; 21(2):149-151. PubMed ID: 25655769
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the risk of inhibitor formation with different factor VIII products.
    Mannucci PM
    Blood; 2006 May; 107(9):3809-10; author reply 3810. PubMed ID: 16627765
    [No Abstract]   [Full Text] [Related]  

  • 14. New treatment for hemophilia.
    FDA Consum; 2003; 37(6):5. PubMed ID: 14983810
    [No Abstract]   [Full Text] [Related]  

  • 15. Surgery in haemophilic patients with inhibitors.
    Rodriguez-Merchan EC
    Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant antihemophilic factor.
    Med Lett Drugs Ther; 1993 Jun; 35(898):51-2. PubMed ID: 8497206
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of hemophilia A with actor VIII concentrate in urological operations and injuries of the urinary tract].
    Brühl P; Weibbach L; Brackmann HH
    MMW Munch Med Wochenschr; 1975 Mar; 117(10):401-4. PubMed ID: 804604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 20. After the SIPPET study: Position paper of the CoMETH, the French society of haemophilia.
    Lebreton A; Castet S; Falaise C; Rugeri L; Schved JF; Wibaut B
    Haemophilia; 2018 Mar; 24(2):e55-e57. PubMed ID: 29316084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.